New perspectives in nuclear neurology for the evaluation of Parkinson's disease

Journal of Parkinson's Disease

Volumn 3, Issue 3, 2013, Pages 301-323

  Benadiba, Marcel ^a,b   Luurtsema, Gert ^a   Tumas, Vitor ^b   Buchpigel, Carlos Alberto ^b   Busatto, Geraldo F ^b  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Lipid metabolism; Parkinson disease; Positron emission tomography; Radioactive tracers; Single photon emission computed tomography

Indexed keywords

1 (2,3 DICHLOROBENZOYL) 5 METHOXY 2 METHYL 3 (2 MORPHOLINOETHYL)INDOLE; AQUAPORIN 4; AQUAPORIN 9; AROMATASE; CARBON ACETOACETATE C 11; CARBON VERAPAMIL C 11; ENDOCANNABINOID; FLUORINE ICMT 11 F 18; FLUORINE MK 9470 F 18; FLURPIRIDAZ F 18; INTERLEUKIN 1; IODINE SD 7015 I 125; N SEC BUTYL 1 (2 CHLOROPHENYL) N METHYL 3 ISOQUINOLINECARBOXAMIDE C 11; POLYUNSATURATED FATTY ACID; TRACER; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

ARTICLE; BRAIN METABOLISM; DIFFERENTIAL DIAGNOSIS; DISEASE COURSE; HUMAN; IMMUNE RESPONSE; ISOTOPE LABELING; LIPID METABOLISM; MITOCHONDRIAL RESPIRATION; MOLECULAR IMAGING; NERVE CELL PLASTICITY; NONHUMAN; PARKINSON DISEASE; POSITRON; PRIORITY JOURNAL; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

ENDOCANNABINOIDS; FATTY ACIDS, UNSATURATED; HOMEOSTASIS; HUMANS; LIPID METABOLISM; MITOCHONDRIA; MOLECULAR IMAGING; NEUROLOGY; NEURONAL PLASTICITY; NUCLEAR MEDICINE; PARKINSON DISEASE; POSITRON-EMISSION TOMOGRAPHY; STRESS, PSYCHOLOGICAL; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 84888859202     PISSN: 18777171     EISSN: 1877718X     Source Type: Journal    
DOI: 10.3233/JPD-130207     Document Type: Article

References (231)

1. Barbosa MT, Caramelli P, Maia DP, Cunningham MCQ, Guerra HL, Lima-Costa MF, & Cardoso F (2006) Parkinsonism and Parkinson's disease in the elderly: A community-based survey in Brazil (the Bambu'i study). Mov Disord, 21, 800-808
2. Park NH (2012) Parkinson disease. JAAPA, 25, 73-74
3. Ferrer I, L'opez-Gonzalez I, Carmona M, Dalf'o E, Pujol A, & Mart'inez A (2012) Neurochemistry and the non-motor aspects of PD. Neurobiol Dis, 46, 508-526
4. Ferrer I (2011) Neuropathology and neurochemistry of nonmotor symptoms in Parkinson's disease. Parkinsons Dis, 2011, 708404
5. Ferrer I, Martinez A, Blanco R, Dalf'o E, & Carmona M (2011) Neuropathology of sporadic Parkinson disease before the appearance of parkinsonism: Preclinical Parkinson disease J Neural Transm, 118, 821-839
6. Tang CC, Poston KL, Dhawan V, & Eidelberg D (2010) Abnormalities in metabolic network activity precede the onset of motor symptoms in Parkinson's disease. J Neurosci, 30, 1049-1056
7. Zhang L, Dong Y, Xu X, & Xu Z (2012) The role of autophagy in Parkinson's disease. Neural Regen Res, 7, 141-145
8. Green DR, Galluzzi L, & Kroemer G (2011) Mitochondria and the autophagy-inflammation-cell death axis in organismal aging. Science, 333, 1109-1112
9. Benadiba M, Luurtsema G,Wichert-Ana L, Buchpigel CA, & Filho GB (2012) New Molecular targets for PET and SPECT imaging in neurodegenerative diseases. Rev Bras Psiquiatr, 34, 125-148
10. Knudsen Gerber DS (2011) Selegiline and rasagiline: Twins or distant cousins? Guidelines. Consult Pharm, 26, 48-51
11. Bakheit AM (1995) Early diagnosis of Parkinson's disease. Postgrad Med J, 71, 151-152
12. Marti'c-Kehl MI, Schibli R,&Schubiger PA (2012) Can animal data predict human outcome? Problems and pitfalls of translational animal research. Eur J Nucl Med Mol Imaging, 39, 1492-1496
13. Kugaya A, Fujita M, & Innis RB (2000) Applications of SPECT imaging of dopaminergic neurotransmission in neuropsychiatric disorders. Ann Nucl Med, 14, 1-9
14. Van Dyck CH, Malison RT, Seibyl JP, Laruelle M, Klumpp H, Zoghbi SS, Baldwin RM, & Innis RB (2000) Age-related decline in central serotonin transporter avail ability with [(123)I]beta-CIT SPECT. Neurobiol Aging, 21, 497-501
15. Pavese N, Simpson BS, Metta V, Ramlackhansingh a, Chaudhuri KR, & Brooks DJ (2012) [18F]FDOPA uptake in the raphe nuclei complex reflects serotonin transporter availability.Acombined [18F]FDOPAand [11C]DASB PET study in Parkinson's disease. NeuroImage, 59, 1080-1084
16. Willmann JK, Van Bruggen N, Dinkelborg LM, & Gambhir SS (2008) Molecular imaging in drug development. Nat Rev Drug Discov, 7, 591-607
17. Pimlott SL, & Sutherland A (2011) Molecular tracers for the PET and SPECT imaging of disease. Chem Soc Rev, 40, 149-162
18. Lipinski CA, Lombardo F, DominyBW,&Feeney PJ (2001) Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev, 46, 3-26
19. Frey KA, Koeppe RA, & Kilbourn MR (2001) Imaging the vesicular monoamine transporter. Adv Neurol, 86, 237-247
20. Brooks DJ (1997) PET and SPECT studies in Parkinson's disease. Baillieres Clin Neurol, 6, 69-87
21. Seibyl JP (2008) Single-photon emission computed tomography and positron emission tomography evaluations of patients with central motor disorders. Semin Nucl Med, 38, 274-286
22. Booij J, Tissingh G, Winogrodzka A, & Van Royen EA (1999) Imaging of the dopaminergic neurotransmission system using single-photon emission tomography and positron emission tomography in patients with parkinsonism. Eur J Nucl Med, 26, 171-182
23. Stoessl AJ (2007) Positron emission tomography in premotor Parkinson's disease. Parkinsonism Relat Disord, 13(Suppl 3), S421-S424
24. Brüggemann N, Hagenah J, Reetz K, Schmidt A, Kasten M, Buchmann I, Eckerle S, Bähre M, Münchau A, Djarmati A, Van der Vegt J, Siebner H, Binkofski F, Ramirez A, Behrens MI, & Klein C (2010) Recessively inherited parkinsonism: Effect of ATP13A2 mutations on the clinical and neuroimaging phenotype. Arch Neurol, 67, 1357-1363
25. Villeda SA, Luo J, Mosher KI, Zou B, Britschgi M, Bieri G, Stan TM, Fainberg N, Ding Z, Eggel A, Lucin KM, Czirr E, Park J-S, Couillard-Despr'es S, Aigner L, Li G, Peskind ER, Kaye JA, Quinn JF, Galasko DR, Xie XS, Rando TA, & Wyss-Coray T (2011) The ageing systemic milieu negatively regulates neurogenesis and cognitive function. Nature, 477, 90-94
26. Ongini E, & Fredholm BB (1996) Pharmacology of adenosine A2A receptors. Trends Pharmacol Sci, 17, 364-372
27. Singer C (2012) Managing the patient with newly diagnosed Parkinson disease. Cleve Clin J Med, 79(Suppl 2), S3-S7
28. Ferr'e S, Fredholm BB, Morelli M, Popoli P, & Fuxe K (1997) Adenosine-dopamine receptor-receptor interactions as an integrative mechanism in the basal ganglia. Trends Neurosci, 20, 482-487
29. Svenningsson P, Le Moine C, Fisone G, & Fredholm BB (1999) Distribution, biochemistry and function of striatal adenosine A2A receptors. Prog Neurobiol, 59, 355-396
30. Vortherms TA, & Watts VJ (2004) Sensitization of neuronalA2Aadenosine receptors after persistent D2 dopamine receptor activation. J Pharmacol Exp Ther, 308, 221-227
31. Aoyama S, Kase H,&Borrelli E (2000) Rescue of locomotor impairment in dopamine D2 receptor-deficient mice by an adenosine A2A receptor antagonist J Neurosci, 20, 5848-5852
32. Fredduzzi S, Moratalla R, Monopoli A, Cuellar B, Xu K, Ongini E, Impagnatiello F, Schwarzschild MA, & Chen J-F (2002) Persistent behavioral sensitization to chronic L-DOPA requires A2A adenosine receptors. J Neurosci, 22, 1054-1062
33. Gomes CV, Kaster MP, Tom'e AR, Agostinho PM, & Cunha RA (2011) Adenosine receptors and brain diseases: Neuroprotection and neurodegeneration. Biochim Biophys Acta, 1808, 1380-1399
34. Armentero M-T, Fancellu R, Nappi G, Bramanti P, & Blandini F (2006) Prolonged blockade of NMDA or mGluR5 glutamate receptors reduces nigrostriatal degeneration while inducing selective metabolic changes in the basal ganglia circuitry in a rodent model of Parkinson's disease. Neurobiol Dis, 22, 1-9
35. Black YD, Xiao D, Pellegrino D, Kachroo A, Brownell A-L, & Schwarzschild MA (2010) Protective effect of metabotropic glutamate mGluR5 receptor elimination in a 6-hydroxydopamine model of Parkinson's disease. Neurosci Lett, 486, 161-165
36. Kachroo A, Orlando LR, Grandy DK, Chen J-F, Young AB, & Schwarzschild MA (2005) Interactions between metabotropic glutamate 5 and adenosine A2A receptors in normal and parkinsonian mice. J Neurosci, 25, 10414-10419
37. Hauser RA, & Schwarzschild MA (2005) Adenosine A2A receptor antagonists for Parkinson's disease: Rationale, therapeutic potential and clinical experience. Drugs Aging, 22, 471-482
38. Hickey P, & Stacy M (2012) Adenosine A2A antagonists in Parkinson's disease: What's next? Curr Neurol Neurosci Rep, 12, 376-385
39. Pinna A, Volpini R, Cristalli G, & Morelli M (2005) New adenosine A2A receptor antagonists: Actions on Parkinson's disease models Eur J Pharmacol, 512, 157-164
40. Fukumitsu N, Ishii K, Kimura Y, Oda K, Sasaki T, Mori Y, & Ishiwata K (2003) Imaging of adenosine A1 receptors in the human brain by positron emission tomography with [11C]MPDX. Ann Nucl Med, 17, 511-515
41. Bauer A, Holschbach MH, Meyer PT, Boy C, Herzog H, Olsson RA, Coenen HH, & Zilles K (2003) In vivo imaging of adenosine A1 receptors in the human brain with [18F]CPFPX and positron emission tomography. NeuroImage, 19, 1760-1769
42. Paul S, Khanapur S, Rybczynska AA, Kwizera C, Sijbesma JWA, Ishiwata K, Willemsen ATM, Elsinga PH, Dierckx RAJO, & van Waarde A (2011) Small-Animal PET study of adenosine A(1) receptors in rat brain: Blocking receptors and raising extracellular adenosine. J Nucl Med, 52, 1293-1300
43. Ramlackhansingh AF, Bose SK, Ahmed I, Turkheimer FE, Pavese N, & Brooks DJ (2011) Adenosine 2A receptor availability in dyskinetic and nondyskinetic patients with Parkinson disease. Neurology, 76, 1811-1816
44. Noguchi J, Ishiwata K, Wakabayashi S, Nariai T, Shumiya S, Ishii S, Toyama H, Endo K, Suzuki F, & Senda M (1998) Evaluation of carbon-11-labeled KF17837:ApotentialCNS adenosine A2a receptor ligand. J Nucl Med, 39, 498-503
45. Ishiwata K, Ogi N, Shimada J, Nonaka H, Tanaka A, Suzuki F, & Senda M (2000) Further characterization of a CNS adenosine A2a receptor ligand [11C]KF18446 with in vitro autoradiography and in vivo tissue uptake. Ann Nucl Med, 14, 81-89
46. Mishina M, Ishiwata K, Naganawa M, Kimura Y, Kitamura S, Suzuki M, Hashimoto M, Ishibashi K, Oda K, Sakata M, Hamamoto M, Kobayashi S, Katayama Y, & Ishii K (2011) Adenosine A(2A) receptors measured with [C]TMSX PET in the striata of Parkinson's disease patients. PloS one, 6, e17338
47. Roussa E, Von Bohlen und Halbach O, & Krieglstein K (2009) TGF-beta in dopamine neuron development, maintenance and neuroprotection. Adv Exp Med Biol, 651, 81-90
48. Bruno V, Battaglia G, Casabona G, Copani A, Caciagli F, & Nicoletti F (1998) Neuroprotection by glial metabotropic glutamate receptors is mediated by transforming growth factor-beta. J Neurosci, 18, 9594-9600
49. Mogi M, Harada M, Kondo T, Narabayashi H, Riederer P,& Nagatsu T (1995) Transforming growth factor-beta 1 levels are elevated in the striatum and in ventricular cerebrospinal fluid in Parkinson's disease. Neurosci Lett, 193, 129-132
50. Dohgu S, Yamauchi A, Takata F, Naito M, Tsuruo T, Higuchi S, Sawada Y, & Kataoka Y (2004) Transforming growth factor-beta1 upregulates the tight junction and Pglycoprotein of brain microvascular endothelial cells. Cell Mol Neurobiol, 24, 491-497
51. Schinkel A (1999) P-Glycoprotein, a gatekeeper in the blood-brain barrier. Adv Drug Deliv Rev, 36, 179-194
52. Abbott NJ (2002) Astrocyte-endothelial interactions and blood-brain barrier permeability. J Anat, 200, 629-638
53. Dobolyi A, Vincze C, P'al G, & Lovas G (2012) The neuroprotective functions of transforming growth factor beta proteins Int J Mol Sci, 13, 8219-8258
54. Tapia-Gonz'alez S, Gir'aldez-P'erez RM, Cuartero MI, Casarejos MJ, Mena MÁ, Wang X-F, & Sa'nchez-Capelo A (2011) Dopamine and α-synuclein dysfunction in Smad3 null mice. Mol Neurodegene, 6, 72
55. Oude Munnink TH, Arjaans MEA, Timmer-Bosscha H, SchröderCP, HesselinkJW,Vedelaar SR,WalenkampAME, Reiss M, Gregory RC, Lub-de Hooge MN, & De Vries EG E (2011) PET with the 89Zr-labeled transforming growth factor-α antibody fresolimumab in tumor models. J Nucl Med, 52, 2001-2008
56. Chung SJ, Armasu SM, Biernacka JM, Lesnick TG, Rider DN, Cunningham JM, & Maraganore DM (2011) Variants in estrogen-related genes and risk of Parkinson's disease. Mov Disord, 26, 1234-1242
57. Morale MC, L'Episcopo F, Tirolo C, Giaquinta G, Caniglia S, Testa N, Arcieri P, Serra P-A, Lupo G, Alberghina M, Harada N, Honda S, Panzica GC,&Marchetti B (2008) Loss of aromatase cytochrome P450 function as a risk factor for Parkinson's disease? Brain res rev, 57, 431-443
58. Roselli CF Brain aromatase: Roles in reproduction and neuroprotection J Steroid Biochem Mol Biol, 106, 143-150
59. Garcia-Segura LM (2008) Aromatase in the brain: Not just for reproduction anymore. J Neuroendocrinol, 20, 705-712
60. Saldanha CJ, Duncan KA, & Walters BJ (2009) Neuroprotective actions of brain aromatase. Front Neuroendocrinol, 30, 106-118
61. Hiltunen M, Iivonen S, & Soininen H (2006) Aromatase enzyme and Alzheimer's disease. Minerva Endocrinol, 31, 61-73
62. Morissette M, Al Sweidi S, Callier S, & Di Paolo T (2008) Estrogen and SERM neuroprotection in animal models of Parkinson's disease. Mol Cell Endocrinol, 290, 60-69
63. Biegon A, KimSW, Alexoff DL, Jayne M, Carter P, Hubbard B, King P, Logan J, Muench L, Pareto D, Schlyer D, Shea C, Telang F, Wang G-J, Xu Y, & Fowler JS (2010) Unique distribution of aromatase in the human brain: In vivo studies with PET and [N-methyl-11C]vorozole. Synapse, 64, 801-807
64. Takahashi K,Yamagishi G, HiramatsuT, Hosoya A, Onoe K, Doi H, Nagata H,Wada Y, Onoe H,Watanabe Y, & Hosoya T (2011) Practical synthesis of precursor of [N-methyl-11C]vorozole, an efficient PET tracer targeting aromatase in the brain. Bioorg Med Chem, 19, 1464-1470
65. Block ML, Zecca L,&Hong J-S (2007) Microglia-mediated neurotoxicity: Uncovering the molecular mechanisms. Nat Rev Neurosci, 8, 57-69
66. Machado A, Herrera AJ, Venero JL, Santiago M, De Pablos RM, Villar'an RF, Espinosa-Oliva AM, Argüelles S, Sarmiento M, Delgado-Cort'es MJ, Mauriño R, & Cano J (2011) Peripheral inflammation increases the damage in animal models of nigrostriatal dopaminergic neurodegeneration: Possible implication in Parkinson's disease incidence. Parkinsons Dis, 2011, 393769
67. Ching ASC, Kuhnast B, Damont A, Roeda D, Tavitian B, & Doll'e F (2012) Current paradigm of the 18-kDa translocator protein (TSPO) as a molecular target for PET imaging in neuroinflammation and neurodegenerative diseases. Insights Imaging, 3, 111-119
68. Arlicot N, Vercouillie J, Ribeiro M-J, Tauber C, Venel Y, Baulieu J-L, Maia S, Corcia P, Stabin MG, Reynolds A, Kassiou M, & Guilloteau D (2011) Initial evaluation in healthy humans of [(18)F]DPA-714, a potential PET biomarker for neuroinflammation. Nucl Med Biol, 39, 570-578
69. Arlicot N, Katsifis A, Garreau L, Mattner F,Vergote J, Duval S,Kousignian I, Bodard S, Guilloteau D,&Chalon S (2008) Evaluation of CLINDE as potent translocator protein (18 kDa) SPECT radiotracer reflecting the degree of neuroinflammation in a rat model of microglial activation Eur J Nucl Med Mol Imaging, 35, 2203-2211
70. Chen M-K, & Guilarte TR (2008) Translocator protein 18 kDa (TSPO): Molecular sensor of brain injury and repair. Pharmacol Ther, 118, 1-17
71. Maia S, Arlicot N, Vierron E, Bodard S, Vergote J, Guilloteau D, & Chalon S (2012) Longitudinal and parallel monitoring of neuroinflammation and neurodegeneration in a 6-hydroxydopamine rat model of Parkinson's disease. Synapse, 66, 573-583
72. Ouchi Y, Yoshikawa E, Sekine Y, Futatsubashi M, Kanno T, Ogusu T, & Torizuka T (2005) Microglial activation and dopamine terminal loss in early Parkinson's disease. Ann Neurol, 57, 168-175
73. Gerhard A, Trender-Gerhard I, Turkheimer F, Quinn NP, BhatiaKP,&Brooks DJ (2006) In vivo imaging of microglial activation with [11C](R)-PK11195 PET in progressive supranuclear palsy. Mov Disord, 21, 89-93
74. Gerhard A, Pavese N, Hotton G, Turkheimer F, Es M, Hammers A, Eggert K, OertelW, Banati RB,&Brooks DJ (2006) In vivo imaging of microglial activation with [11C](R)-PK11195 PET in idiopathic Parkinson's disease. Neurobiol Dis, 21, 404-412
75. Bartels AL, Willemsen ATM, Doorduin J, De Vries EFJ, Dierckx RA, & Leenders KL (2010) [11C]-PK11195 PET: Quantification of neuroinflammation and a monitor of anti-inflammatory treatment in Parkinson's disease? Parkinsonism Relat Disord, 16, 57-59
76. Doorduin J, Klein HC, Dierckx RA, James M, Kassiou M,& de Vries EFJ (2009) [11C]-DPA-713 and [18F]-DPA-714 as new PET tracers for TSPO: A comparison with [11C]-(R)-PK11195 in a rat model of herpes encephalitis. Mol Imaging Biol, 11, 386-398
77. Arlicot N, Petit E, Katsifis A, Toutain J, Divoux D, Bodard S, Roussel S, Guilloteau D, Bernaudin M, & Chalon S (2010) Detection and quantification of remote microglial activation in rodent models of focal ischaemia using the TSPO radioligand CLINDE. Eur J Nucl Med Mol Imaging, 37, 2371-2380
78. Mattner F, Bandin DL, Staykova M, Berghofer P, Gregoire MC, Ballantyne P, Quinlivan M, Fordham S, Pham T, Willenborg DO, & Katsifis A (2011) Evaluation of [123I]-CLINDE as a potent SPECT radiotracer to assess the degree of astroglia activation in cuprizone-induced neuroinflammation. Eur J Nucl Med Mol Imaging, 38, 1516-1528
79. Zubal G, Jennings D, Tamagnan G, Koren A, Katsifis A, Marek K, Russell D, & Seibyl J (2009) Initial Parkinson's and healthy control studies of 123-I CLINDE, a SPECT marker of the peripheral benzodiazepine receptor and neuroinflammation. Society of Nuclear Medicine Annual Meeting Abstract, 50, 1221
80. Frankola KA, Greig NH, Luo W, & Tweedie D (2011) Targeting TNFα- to elucidate and ameliorate neuroinflammation in neurodegenerative diseases. CNS Neurol Disord Drug Targets, 10, 391-403
81. Mogi M, Harada M, Riederer P, Narabayashi H, Fujita K, & Nagatsu T (1994) Tumor necrosis factor-Alpha (TNFalpha) increases both in the brain and in the cerebrospinal fluid from parkinsonian patients. Neurosci Lett, 165, 208-210
82. Montgomery SL, & Bowers WJ (2012) Tumor necrosis factor-Alpha and the roles it plays in homeostatic and degenerative processes within the central nervous system. J Neuroimmune Pharmacol, 7, 42-59
83. Gordon R, Anantharam V, Kanthasamy AG, & Kanthasamy A (2012) Proteolytic activation of proapoptotic kinase protein kinase Cδ by tumor necrosis factor α death receptor signaling in dopaminergic neurons during neuroinflammation. J Neuroinflammation, 9, 82
84. Cao Q, CaiW, Li Z-B, Chen K, He L, Li H-C, Hui M,&Chen X (2007) PET imaging of acute and chronic inflammation in living mice Eur J Nucl Med Mol Imaging, 34, 1832-1842
85. Anderson CJ, & Ferdani R (2009) Copper-64 radiopharmaceuticals for PET imaging of cancer: Advances in preclinical and clinical research. Cancer Biother Radiopharm, 24, 379-393
86. Feldmann M, Charles P, Taylor P, & Maini RN (1998) Biological insights from clinical trials with anti-TNF therapy Springer Semin Immunopathol, 20, 211-228
87. Gao M, Lola CM, Wang M, Miller KD, Sledge GW, Hutchins GD, & Zheng Q-H (2010) Synthesis of carbon-11-labeled tricyclic necroptosis inhibitors as new potential PETagents for imaging of tumor necrosis factor alpha (TNFalpha). Appl Radiat Isot, 68, 1950-1958
88. Chu W-M (2013) Tumor necrosis factor. Cancer lett, 328, 222-225
89. Mogi M, Harada M,KondoT, Riederer P, Inagaki H, Minami M, & Nagatsu T (1994) Interleukin-1 beta, interleukin-6, epidermal growth factor and transforming growth factoralpha are elevated in the brain from parkinsonian patients. Neurosci Lett, 180, 147-150
90. Ferrari CC, Pott Godoy MC, Tarelli R, Chertoff M, Depino AM,&Pitossi FJ (2006) Progressive neurodegeneration and motor disabilities induced by chronic expression of IL-1beta in the substantia nigra. Neurobiol Dis, 24, 183-193
91. Pott Godoy MC, Tarelli R, Ferrari CC, Sarchi MI, & Pitossi FJ (2008) Central and systemic IL-1 exacerbates neurodegeneration and motor symptoms in a model of Parkinson's disease. Brain, 131, 1880-1894
92. Allan SM, Tyrrell PJ, & Rothwell NJ (2005) Interleukin-1 and neuronal injury. Nat Rev Immunol, 5, 629-640
93. Lucas S-M, Rothwell NJ, Gibson RM (2006) The role of inflammation in CNS injury and disease. Br J Pharmacol, 147 (Suppl), S232-S240
94. Shaftel SS, Kyrkanides S, Olschowka JA, Miller JH, Johnson RE, & O'Banion MK (2007) Sustained hippocampal IL-1 beta overexpression mediates chronic neuroinflammation and ameliorates Alzheimer plaque pathology. J Clin Invest, 117, 1595-1604
95. Shaftel SS, GriffinWST,&O'BanionM K (2008) The role of interleukin-1 in neuroinflammation and Alzheimer disease: An evolving perspective J Neuroinflammation, 5, 7
96. Tansey MG, McCoy MK, & Frank-Cannon TC (2007) Neuroinflammatory mechanisms in Parkinson's disease: Potential environmental triggers, pathways, and targets for early therapeutic intervention. Exp Neurol, 208, 1-25
97. Emsley HCA, Smith CJ, Georgiou RF, Vail A, Hopkins SJ, Rothwell NJ, & Tyrrell PJ (2005) A randomised phase II study of interleukin-1 receptor antagonist in acute stroke patients. J Neurol Neurosurg Psychiatry, 76, 1366-1372
98. Freeman BD, & Buchman TG (2001) Interleukin-1 receptor antagonist as therapy for inflammatory disorders. Expert Opin Biol Ther, 1, 301-308
99. Barksby HE, Lea SR, Preshaw PM, & Taylor JJ (2007) The expanding family of interleukin-1 cytokines and their role in destructive inflammatory disorders. Clin Exp Immunol, 149, 217-225
100. Cawthorne C, Prenant C, Smigova A, Julyan P, Maroy R, Herholz K, Rothwell N, & Boutin H (2011) Biodistribution, pharmacokinetics and metabolism of interleukin-1 receptor antagonist (IL-1RA) using [18F]-IL1RA and PET imaging in rats. Br J Pharmacol, 162, 659-672
101. Liu Z, Wyffels L, Barber C, Hui MM, & Woolfenden JM (2011) A (99m)Tc-labeled dual-domain cytokine ligand for imaging of inflammation. Nucl Med Biol, 38, 795-805
102. Puren AJ, Fantuzzi G, Gu Y, Su MS, & Dinarello CA (1998) Interleukin-18 (IFNgamma-inducing factor) induces IL-8 and IL-1beta via TNFalpha production from non-CD14 + human blood mononuclear cells. J Clin Invest, 101, 711-721
103. Novick D, Kim SH, Fantuzzi G, Reznikov LL, Dinarello CA, & Rubinstein M (1999) Interleukin-18 binding protein: A novel modulator of the Th1 cytokine response. Immunity, 10, 127-136
104. Rentzos M, Nikolaou C, Andreadou E, Paraskevas GP, Rombos A, Zoga M, Tsoutsou A, Boufidou F, Kapaki E, & Vassilopoulos D (2009) Circulating interleukin-10 and interleukin-12 in Parkinson's disease. Acta Neurol Scand, 119, 332-337
105. Stoll G, Jander S, & Schroeter M (2000) Cytokines in CNS disorders: Neurotoxicity versus neuroprotection. J Neural Transm, 59, 81-89
106. Annovazzi A, D'Alessandria C, Bonanno E, Mather SJ, Cornelissen B,Van deWiele C, Dierckx RA, Mattei M, Palmieri G, Scopinaro F, & Signore A (2006) Synthesis of 99mTc-HYNIC-interleukin-12, a new specific radiopharmaceutical for imaging T lymphocytes Eur J Nucl Med Mol Imaging, 33, 474-482
107. Gonzalez-Cuyar LF, Sonnen JA, Montine KS, Keene CD,& Montine TJ (2011) Role of cerebrospinal fluid and plasma biomarkers in the diagnosis of neurodegenerative disorders and mild cognitive impairment. Curr Neurol Neurosci Rep, 11, 455-463
108. Keane PC, Kurzawa M, Blain PG, & Morris CM (2011) Mitochondrial dysfunction in Parkinson's disease. Parkinsons Dis, 2011, 716871
109. Chinta SJ, Mallajosyula JK, Rane A,&Andersen JK (2010) Mitochondrial α-synuclein accumulation impairs complex I function in dopaminergic neurons and results in increased mitophagy in vivo. Neurosci Lett, 486, 235-239
110. Shim JH, Yoon SH, Kim K-H, Han JY, Ha J-Y, Hyun DH, Paek SH, Kang UJ, Zhuang X,&Son JH (2011) The antioxidant Trolox helps recovery from the familial Parkinson's disease-specific mitochondrial deficits caused by PINK1-And DJ-1-deficiency in dopaminergic neuronal cells. Mitochondrion, 11, 707-715
111. Müftüoglu M, Elibol B, Dalmizrak O, Ercan A, Kulaksiz G, Ogüs H, DalkaraT,&Ozer N (2004) Mitochondrial complex I and IV activities in leukocytes from patients with parkin mutations. Mov Disord, 19, 544-548
112. Gomez C, Bandez MJ, & Navarro A (2007) Pesticides and impairment of mitochondrial function in relation with the parkinsonian syndrome. Front Biosci, 12, 1079-1093
113. Yu M, Guaraldi M, Kagan M, Mistry M, McDonald J, Bozek J, Yalamanchili P, Hayes M, Azure M, Purohit A, Radeke H, Casebier DS, & Robinson SP (2009) Assessment of 18F-labeled mitochondrial complex I inhibitors as PET myocardial perfusion imaging agents in rats, rabbits, and primates. Eur J Nucl Med Mol Imaging, 36, 63-72
114. Fukumoto D, Nishiyama S, Harada N, Yamamoto S, & Tsukada H (2012) Detection of ischemic neuronal damage with [18F]BMS-747158-02, a mitochondrial complex-1 positron emission tomography ligand: Small animal PET study in rat brain. Synapse, 66, 909-917
115. VanBrocklin HF, Hanrahan SM, Enas JD, Nandanan E, & O'Neil JP (2007) Mitochondrial avid radioprobes. Preparation and evaluation of 7'(Z)-[125I]iodorotenone and 7'(Z)-[125I]iodorotenol. Nucl Med Biol, 34, 109-116
116. Borghammer P, Cumming P, Østergaard K, Gjedde A, Rodell A, Bailey CJ, & Vafaee MS (2012) Cerebral oxygen metabolism in patients with early Parkinson's disease J Neurol Sci, 313, 123-128
117. Freemantle E, Vandal M, Tremblay Mercier J, Plourde M, Poirier J, & Cunnane SC (2009) Metabolic response to a ketogenic breakfast in the healthy elderly. J Nutr, 13, 293-298
118. Visser FC (2001) Imaging of cardiac metabolism using radiolabelled glucose, fatty acids and acetate. Coronary Artery Dis, 12(Suppl 1), S12-S18
119. Schöder H, & Larson SM (2004) Positron emission tomography for prostate, bladder, and renal cancer. Semin Nucl Med, 34, 274-292
120. Pifferi F, Tremblay S, Croteau E, Fortier M, Tremblay-Mercier J, Lecomte R, & Cunnane SC (2011) Mild experimental ketosis increases brain uptake of 11Cacetoacetate and 18F-fluorodeoxyglucose: A dual-Tracer PET imaging study in rats. Nutr Neurosci, 14, 51-58
121. Elstner M, Morris CM, Heim K, Bender A, Mehta D, Jaros E, Klopstock T, Meitinger T, Turnbull DM, & Prokisch H (2011) Expression analysis of dopaminergic neurons in Parkinson's disease and aging links transcriptional dysregulation of energy metabolism to cell death. Acta Neuropathol, 122, 75-86
122. Lim JH, Kim K-M, Kim SW, Hwang O, & Choi HJ (2008) Bromocriptine activates NQO1 via Nrf2-PI3K/Akt signaling: Novel cytoprotective mechanism against oxidative damage. Pharmacol Res, 57, 325-331
123. Nakaso K, Ito S, & Nakashima K (2008) Caffeine activates the PI3K/Akt pathway and prevents apoptotic cell death in a Parkinson's disease model of SH-SY5Y cells. Neurosci Lett, 432, 146-150
124. Quesada A, Lee BY, &Micevych PE (2008) PI3 kinase/Akt activation mediates estrogen and IGF-1 nigral DA neuronal neuroprotection against a unilateral rat model of Parkinson's disease. Dev Neurobiol, 68, 632-644
125. Malagelada C, Jin ZH, Jackson-Lewis V, Przedborski S, & Greene LA (2010) Rapamycin protects against neuron death in in vitro and in vivo models of Parkinson's disease. J Neurosci, 30, 1166-1175
126. Wang M, Gao M, Miller KD, Sledge GW, & Zheng Q-H (2012) [11C]GSK2126458 and [18F]GSK2126458, the first radiosynthesis of new potential PET agents for imaging of PI3K and mTOR in cancers. Bioorg Med Chem Lett, 22, 1569-1574
127. Di MarzoV, Bifulco M,&De Petrocellis L (2004) The endocannabinoid system and its therapeutic exploitation. Nat Rev Drug Discov, 3, 771-784
128. Scotter EL, Abood ME, & Glass M (2010) The endocannabinoid system as a target for the treatment of neurodegenerative disease. Br J Pharmacol, 160, 480-498
129. Gowran A, Noonan J, & Campbell VA (2011) The multiplicity of action of cannabinoids: Implications for treating neurodegeneration. CNS Neurosci Ther, 17, 637-644
130. Ram'irez BG, Bl'azquez C, G'omez Del Pulgar T, Guzm'an M, & De Ceballos ML (2005) Prevention of Alzheimer's disease pathology by cannabinoids: Neuroprotection mediated by blockade of microglial activation. J Neurosci, 25, 1904-1913
131. Lou Z-Y, Chen C, He Q, Zhao C-B, & Xiao B-G (2011) Targeting CB(2) receptor as a neuroinflammatory modulator in experimental autoimmune encephalomyelitis. Mol Immunol, 49, 453-461
132. Benito C,N'uñez E,Tol'onRM,Carrier EJ,R'abano A, Hillard CJ,&Romero J (2003) CannabinoidCB2receptors and fatty acid amide hydrolase are selectively overexpressed in neuritic plaque-Associated glia in Alzheimer's disease brains. J Neurosci, 23, 11136-11141
133. Katona I, & Freund TF (2008) Endocannabinoid signaling as a synaptic circuit breaker in neurological disease. Nat Med, 14, 923-930
134. Horti AG, Fan H, Kuwabara H, Hilton J, Ravert HT, Holt DP, Alexander M, Kumar A, Rahmim A, Scheffel U,Wong DF,&Dannals RF (2006) 11C-JHU75528:Aradiotracer for PET imaging of CB1 cannabinoid receptors J Nucl Med, 47, 1689-1696
135. Terry GE, Hirvonen J, Liow J-S, Zoghbi SS, Gladding R, Tauscher JT, Schaus JM, Phebus L, Felder CC, Morse CL, Donohue SR, PikeVW, Halldin C,&Innis RB (2010) Imaging and quantitation of cannabinoid CB1 receptors in human and monkey brains using (18)F-labeled inverse agonist radioligands J Nucl Med, 51, 112-120
136. Terry GE, Liow J-S, Zoghbi SS, Hirvonen J, Farris AG, Lerner A, Tauscher JT, Schaus JM, Phebus L, Felder CC, Morse CL, Hong JS, Pike VW, Halldin C, & Innis RB (2009) Quantitation of cannabinoidCB1receptors in healthy human brain using positron emission tomography and an inverse agonist radioligand. NeuroImage, 48, 362-370
137. Terry G, Liow J-S, Chernet E, Zoghbi SS, Phebus L, Felder CC, Tauscher J, Schaus JM, Pike VW, Halldin C, & Innis RB (2008) Positron emission tomography imaging using an inverse agonist radioligand to assess cannabinoid CB1 receptors in rodents. NeuroImage, 41, 690-698
138. Yasuno F, Brown AK, Zoghbi SS, Krushinski JH, Chernet E, Tauscher J, Schaus JM, Phebus LA, Chesterfield AK, Felder CC, Gladding RL, Hong J, Halldin C, Pike VW, & Innis RB (2008) The PET radioligand [11C]MePPEP binds reversibly and with high specific signal to cannabinoid CB1 receptors in nonhuman primate brain. Neuropsychopharmacology, 33, 259-269
139. Casteels C, Koole M, Celen S, Bormans G, & Van Laere K (2012) Preclinical evaluation and quantification of [(18)F]MK-9470 as a radioligand for PET imaging of the type 1 cannabinoid receptor in rat brain. Eur J Nucl Med Mol Imaging, 39, 1467-1477
140. Van Laere K, Casteels C, Lunskens S, Goffin K, Grachev ID, Bormans G, & Vandenberghe W (2012) Regional changes in type 1 cannabinoid receptor availability in Parkinson's disease in vivo. Neurobiol Aging, 33, 620.e1-8
141. Farkas S, Nagy K, Jia Z, Harkany T, Palkovits M, Donohou SR, Pike VW, Halldin C, M'ath'e D, Csiba L, & Guly'as B (2012) The decrease of dopamine D2/D3 receptor densities in the putamen and nucleus caudatus goes parallel with maintained levels of CB1 cannabinoid receptors in Parkinson's disease: A preliminary autoradiographic study with the selective dopamine D2/D3 antagoni. Brain Res Bull, 87, 504-510
142. Turkman N, Shavrin A, Ivanov RA, Rabinovich B,Volgin A, Gelovani JG, & Alauddin MM (2011) Fluorinated cannabinoid CB2 receptor ligands: Synthesis and in vitro binding characteristics of 2-oxoquinoline derivatives. Bioorg Med Chem, 19, 5698-5707
143. Turkman N, Shavrin A, Paolillo V, Yeh HH, Flores L, Soghomonian S, Rabinovich B, Volgin A, Gelovani J, & Alauddin M (2012) Synthesis and preliminary evaluation of ]-labeled 2-oxoquinoline derivatives for PET imaging of cannabinoid CB2 receptor Nucl Med Biol, 39, 593-600
144. Evens N,Vandeputte C, Muccioli GG, Lambert DM, Baekelandt V, Verbruggen AM, Debyser Z, Van Laere K, & Bormans GM (2011) Synthesis, in vitro and in vivo evaluation of fluorine-18 labelled FE-GW405833 as a PET tracer for type 2 cannabinoid receptor imaging. Bioorg Med Chem, 19, 4499-4505
145. Battista N, Bari M, Tarditi A, Mariotti C, Bachoud-L'evi AC, Zuccato C, Finazzi-Agrò A, Genitrini S, Peschanski M, Di Donato S, Cattaneo E, & Maccarrone M (2007) Severe deficiency of the fatty acid amide hydrolase (FAAH) activity segregates with the Huntington's disease mutation in peripheral lymphocytes. Neurobiol Dis, 27, 108-116
146. Mattammal MB, Strong R, Lakshmi VM, Chung HD, & Stephenson AH (1995) Prostaglandin H synthetasemediated metabolism of dopamine: Implication for Parkinson's disease. J Neurochem, 64, 1645-1654
147. Zhang W, Wang T, Pei Z, Miller DS, Wu X, Block ML, Wilson B, Zhang W, Zhou Y, Hong J-S, & Zhang J (2005) Aggregated alpha-synuclein activates microglia: A process leading to disease progression in Parkinson's disease. FASEB J, 19, 533-542
148. Golovko MY, Barcel'o-Coblijn G, Castagnet PI, Austin S, Combs CK, & Murphy EJ (2009) The role of alphasynuclein in brain lipid metabolism: A downstream impact on brain inflammatory response. Mol Cell Biochem, 326, 55-66
149. Castagnet PI, Golovko MY, Barcel'o-Coblijn GC, Nussbaum RL, & Murphy EJ (2005) Fatty acid incorporation is decreased in astrocytes cultured from alpha-synuclein gene-Ablated mice J Neurochem, 94, 839-849
150. Ellis CE, Murphy EJ, Mitchell DC, GolovkoMY, Scaglia F, Barcel'o-Coblijn GC,&NussbaumR L (2005) Mitochondrial lipid abnormality and electron transport chain impairment in mice lacking alpha-synuclein. Mol Cell Biol, 25, 10190-10201
151. Wyffels L, Muccioli GG, De Bruyne S, Moerman L, Sambre J, Lambert DM, & De Vos F (2009) Synthesis, in vitro and in vivo evaluation, and radiolabeling of aryl anandamide analogues as candidate radioligands for in vivo
152. Wyffels L, Muccioli GG, Kapanda CN, Labar G, De Bruyne S, De Vos F, & Lambert DM (2010) PET imaging of fatty acid amide hydrolase in the brain: Synthesis and biological evaluation of an 11C-labelled URB597 analogue. Nucl Med Biol, 37, 665-675
153. Wilson AA, Garcia A, Parkes J, Houle S, Tong J, & Vasdev N (2011) [11C]CURB: Evaluation of a novel radiotracer for imaging fatty acid amide hydrolase by positron emission tomography. Nucl Med Biol, 38, 247-253
154. Skaddan MB, Zhang L, Johnson DS, Zhu A, Zasadny KR, Coelho RV, Kuszpit K, Currier G, Fan K-H, Beck EM, Chen L, Drozda SE, Balan G, Niphakis M, Cravatt BF, Ahn K, Bocan T, & Villalobos A (2012) The synthesis and in vivo evaluation of [(18)F]PF-9811:Anovel PET ligand for imaging brain fatty acid amide hydrolase (FAAH). NuclMedBiol, 39, 1058-1067
155. Li GL, Winter H, Arends R, Jay GW, Le V, Young T, & Huggins JP (2012) Assessment of the pharmacology and tolerability of PF-04457845, an irreversible inhibitor of fatty acid amide hydrolase-1, in healthy subjects. Br J Clin Pharmacol, 73, 706-716
156. Rapoport SI, Chang MC, Spector AA (2001) Delivery and turnover of plasma-derived essential PUFAs in mammalian brain. J Lipid Res, 42, 678-685
157. Rapoport SI (2008) Arachidonic acid and the brain. J Nutr, 138, 2515-2520
158. Bazan NG, Molina MF, & Gordon WC (2011) Docosahexaenoic acid signalolipidomics in nutrition: Significance in aging, neuroinflammation, macular degeneration, Alzheimer's, and other neurodegenerative diseases. Annu Rev Nutr, 31, 321-351
159. Zhang C,&Bazan NG (2010) Lipid-mediated cell signaling protects against injury and neurodegeneration. J Nutr, 140, 858-863
160. Drukarch B, & Van Muiswinkel FL (2001) Neuroprotection for Parkinson's disease: A new approach for a new millennium. Expert Opin Investig Drugs, 10, 1855-1868
161. Ferrer I (2009) Altered mitochondria, energy metabolism, voltage-dependent anion channel, and lipid rafts converge to exhaust neurons in Alzheimer's disease. J Bioenerg Biomembr, 41, 425-431
162. Dalf'o E, Portero-Ot'in M, Ayala V, Mart'inez A, Pamplona R, & Ferrer I (2005) Evidence of oxidative stress in the neocortex in incidental Lewy body disease. J Neuropathol Exp Neurol, 64, 816-830
163. Fabelo N, Mart'in V, Santpere G, Mar'in R, Torrent L, Ferrer I, & D'iaz M (2011) Severe alterations in lipid composition of frontal cortex lipid rafts from Parkinson's disease and incidental Parkinson's disease. Mol Med, 17, 1107-1118
164. Sharon R, Bar-Joseph I, Mirick GE, Serhan CN, & Selkoe DJ (2003) Altered fatty acid composition of dopaminergic neurons expressing alpha-synuclein and human brains with alpha-synucleinopathies. J Biol Chem, 278, 49874-49881
165. Luchtman DW, Meng Q, & Song C (2012) Ethyleicosapentaenoate (E-EPA) attenuates motor impairments and inflammation in the MPTP-probenecid mouse model of Parkinson's disease. Behav Brain Res, 226, 386-396
166. Meng Q, Luchtman DW, El Bahh B, Zidichouski JA, Yang J, & Song C (2010) Ethyl-eicosapentaenoate modulates changes in neurochemistry and brain lipids induced by parkinsonian neurotoxin 1-methyl-4-phenylpyridinium in mouse brain slices. Eur J Pharmacol, 649, 127-134
167. Lin P-Y, Chiu C-C, Huang S-Y, & Su K-P (2012) A metaanalytic review of polyunsaturated fatty acid compositions in dementia. J Clin Psychiatry 1245-1254
168. Dexter DT, Carter CJ,Wells FR, Javoy-Agid F, AgidY, Lees A, Jenner P, & Marsden CD (1989) Basal lipid peroxidation in substantia nigra is increased in Parkinson's disease. J Neurochem, 52, 381-389
169. Yoritaka A, Hattori N, Uchida K, Tanaka M, Stadtman ER, & Mizuno Y (1996) Immunohistochemical detection of 4-hydroxynonenal protein adducts in Parkinson disease. Proc Natl Acad Sci USA, 93, 2696-2701
170. Rapoport SI, Ramadan E, & Basselin M (2011) Docosahexaenoic acid (DHA) incorporation into the brain from plasma, as an in vivo biomarker of brain DHA metabolism and neurotransmission. Prostaglandins Other Lipid Mediat, 96, 109-113
171. Ouellet M, Emond V, Chen CT, Julien C, Bourasset F, Oddo S, LaFerla F, Bazinet RP, & Calon F (2009) Diffusion of docosahexaenoic and eicosapentaenoic acids through the blood-brain barrier: An in situ cerebral perfusion study. Neurochem Int, 55, 476-482
172. Rapoport SI (2003) In vivo approaches to quantifying and imaging brain arachidonic and docosahexaenoic acid metabolism. J Pediatr, 143, S26-S34
173. Robinson PJ, Noronha J, DeGeorge JJ, Freed LM, Nariai T, & Rapoport SI (1992) A quantitative method for measuring regional in vivo fatty-Acid incorporation into and turnover within brain phospholipids: Review and critical analysis. Brain Res, 17, 187-214
174. Scarselli M, Armogida M, Pardini C, Chiacchio S,&Corsini GU (2001) Apomorphine. A novel effect for an old compound. Adv Neurol, 86, 367-372
175. Thambisetty M, Gallardo KA, Liow J-S, Beason-Held LL, Umhau JC, Bhattacharjee AK, Der M, Herscovitch P, Rapoport JL, & Rapoport SI (2012) The utility of (11)C-Arachidonate PET to study in vivo dopaminergic neurotransmission in humans. J Cereb Blood Flow Metab, 32, 676-684
176. Elliott PN, Jenner P, Huizing G, Marsden CD, & Miller R (1977) Substituted benzamides as cerebral dopamine antagonists in rodents. Neuropharmacology, 16, 333-342
177. Esposito G, Giovacchini G, Liow J-S, Bhattacharjee AK, Greenstein D, Schapiro M, Hallett M, Herscovitch P, Eckelman WC, Carson RE, Rapoport SI (2008) Imaging neuroinflammation in Alzheimer's disease with radiolabeled arachidonic acid and PET. J Nucl Med, 49, 1414-1421
178. Leng Y, & Chuang D-M (2006) Endogenous alphasynuclein is induced by valproic acid through histone deacetylase inhibition and participates in neuroprotection against glutamate-induced excitotoxicity. J Neurosci, 26, 7502-7512
179. Quilty MC, King AE, Gai W-P, Pountney DL, West AK, Vickers JC,&Dickson TC (2006) Alpha-synuclein is upregulated in neurones in response to chronic oxidative stress and is associated with neuroprotection. Exp Neurol, 199, 249-256
180. Sidhu A, Wersinger C, Moussa CE-H, & Vernier P (2004) The role of alpha-synuclein in both neuroprotection and neurodegeneration. Ann N Y Acad Sci, 1035, 250-270
181. Luurtsema G, Molthoff CFM, Windhorst AD, Smit JW, Keizer H, Boellaard R, Lammertsma AA, & Franssen EJF (2003) (R)-And (S)-[11C]verapamil as PET-Tracers for measuring P-glycoprotein function: In vitro and in vivo evaluation. Nucl Med Biol, 30, 747-751
182. Luurtsema G, Schuit RC, Klok RP, Verbeek J, Leysen JE, Lammertsma A, a, & Windhorst AD (2009) Evaluation of [11C]laniquidar as a tracer of P-glycoprotein: Radiosynthesis and biodistribution in rats. Nucl Med Biol, 36, 643-649
183. Kortekaas R, Leenders KL, van Oostrom JCH, VaalburgW, Bart J, Willemsen ATM, & Hendrikse NH (2005) Bloodbrain barrier dysfunction in parkinsonian midbrain in vivo. Ann Neurol, 57, 176-179
184. Bartels AL, Willemsen ATM, Kortekaas R, de Jong BM, de Vries R, de Klerk O, van Oostrom JCH, Portman A, & Leenders KL (2008) Decreased blood-brain barrier Pglycoprotein function in the progression of Parkinson's disease, PSP and MSA. J Neural Transm, 115, 1001-1009
185. Bartels AL, Van Berckel BNM, Lubberink M, Luurtsema G, Lammertsma AA, & Leenders KL (2008) Blood-brain barrier P-glycoprotein function is not impaired in early Parkinson's disease. Parkinsonism Relat Disord, 14, 505-508
186. Bartels AL, Kortekaas R, Bart J,Willemsen ATM, De Klerk OL, De Vries JJ, Van Oostrom JCH, & Leenders KL (2009) Blood-brain barrier P-glycoprotein function decreases in specific brain regions with aging:Apossible role in progressive neurodegeneration. Neurobiol Aging, 30, 1818-1824
187. Toornvliet R, Van Berckel BNM, Luurtsema G, Lubberink M, Geldof A, a, Bosch TM, Oerlemans R, Lammertsma A, a, & Franssen EJF (2006) Effect of age on functional P-glycoprotein in the blood-brain barrier measured by use of (R)-[(11)C]verapamil and positron emission tomography. Clin Pharmacol Ther, 79, 540-548
188. Luurtsema G, Molthoff CFM, Schuit RC, Windhorst AD, Lammertsma AA,&Franssen EJF (2005) Evaluation of (R)-[11C]verapamil as PET tracer of P-glycoprotein function in the blood-brain barrier: Kinetics and metabolism in the rat. Nucl Med Biol, 32, 87-93
189. Lubberink M, Luurtsema G, van BerckelBNM,Boellaard R, Toornvliet R,Windhorst AD, Franssen EJF, & Lammertsma AA (2007) Evaluation of tracer kinetic models for quantification of P-glycoprotein function using (R)-[11C]verapamil and PET. J Cereb Blood Flow Metab, 27, 424-433
190. VanWaarde A, Ramakrishnan NK, Rybczynska AA, Elsinga PH, Berardi F, de Jong JR, Kwizera C, Perrone R, Cantore M, Sijbesma JWA, Dierckx RA, & Colabufo NA (2009) Synthesis and preclinical evaluation of novel PET probes for P-glycoprotein function and expression. J Med Chem, 52, 4524-4532
191. Colabufo NA, Berardi F, Cantore M, Contino M, Inglese C, Niso M, & Perrone R (2010) Perspectives of P-glycoprotein modulating agents in oncology and neurodegenerative diseases: Pharmaceutical, biological, and diagnostic potentials. J Med Chem, 53, 1883-1897
192. Mairinger S,Wanek T,Kuntner C, DoenmezY, Strommer S, Stanek J, Capparelli E, Chiba P,Müller M, Colabufo NA, & Langer O (2012) Synthesis and preclinical evaluation of the radiolabeled P-glycoprotein inhibitor [(11)C]MC113. Nucl Med Biol, 39, 1219-1225
193. Wanek T, Kuntner C, Bankstahl JP, Mairinger S, Bankstahl M, Stanek J, Sauberer M, FilipT, ErkerT,Müller M,Löscher W, & Langer O (2012) A novel PET protocol for visualization of breast cancer resistance protein function at the blood-brain barrier. J Cereb Blood Flow Metab, 32, 2002-2011
194. Kannan P, Telu S, Shukla S, Ambudkar SV, Pike VW, Halldin C, Gottesman MM, Innis RB, & Hall MD (2011) The "specific" P-glycoprotein inhibitor tariquidar is also a substrate and an inhibitor for breast cancer resistance protein (BCRP/ABCG2). ACS Chem Neurosci, 2, 82-89
195. ElAli A,&HermannD M (2011)ATP-binding cassette transporters and their roles in protecting the brain. Neuroscientist, 17, 423-436
196. Agarwal S, & Elmquist WF (2012) Insight into the cooperation of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) at the blood-brain barrier: A case study examining Sorafenib efflux clearance. Mol Pharm, 9, 678-684
197. Do TM, Noel-Hudson M-S, Ribes S, Besengez C, Smirnova M, Cisternino S, Buyse M, Calon F, Chimini G, Chacun H, Scherrmann J-M, Farinotti R, & Bourasset F (2012) ABCG2-And ABCG4-mediated efflux of amyloid-peptide 1-40 at the mouse blood-brain barrier. J Alzheimers Dis, 30, 155-166
198. Xiong H, Callaghan D, Jones A, Bai J, Rasquinha I, Smith C, Pei K, Walker D, Lue L, Stanimirovic D, & Zhang W (2009) ABCG2 is upregulated in Alzheimer's brain with cerebral amyloid angiopathy and may act as a gatekeeper at the blood-brain barrier for Abeta(1-40) peptides. J Neurosci, 29, 5463-5475
199. Brenn A, Grube M, Peters M, Fischer A, Jedlitschky G, Kroemer HK, Warzok RW, & Vogelgesang S (2011) Betaamyloid downregulates MDR1-P-glycoprotein (Abcb1) expression at the blood-brain barrier in mice Int J Alzheimers Dis, 2011, 690121
200. Bartels AL (2011) Blood-brain barrier P-glycoprotein function in neurodegenerative disease. Curr Pharm Des, 17, 2771-2777
201. Dörner B, Kuntner C, Bankstahl JP, Wanek T, Bankstahl M, Stanek J, Müllauer J, Bauer F, Mairinger S, Löscher W, Miller DW, Chiba P, Müller M, Erker T, & Langer O (2011) Radiosynthesis and in vivo evaluation of 1-[18F]fluoroelacridar as a positron emission tomography tracer for P-glycoprotein and breast cancer resistance protein. Bioorg Med Chem, 19, 2190-2198
202. Badaut J, Lasbennes F, Magistretti PJ, & Regli L (2002) Aquaporins in brain: Distribution, physiology, and pathophysiology. J Cereb Blood Flow Metab, 22, 367-378
203. Foglio E, & Rodella LF (2010) Aquaporins and neurodegenerative diseases. Curr Neuropharmacol, 8, 112-121
204. Hao C, Liu W, Luan X, Li Y, Gui H, Peng Y, Shen J, Hu G, & Yang J (2010) Aquaporin-4 knockout enhances astrocyte toxicity induced by 1-methyl-4-phenylpyridinium ion and lipopolysaccharide via increasing the expression of cytochrome P4502E1. Toxicol Lett, 198, 225-231
205. Küppers E, Gleiser C, Brito V, Wachter B, Pauly T, Hirt B, & Grissmer S (2008) AQP4 expression in striatal primary cultures is regulated by dopamine-implications for proliferation of astrocytes. Eur J Neurosci, 28, 2173-2182
206. Nicchia GP, Frigeri A, Liuzzi GM, & Svelto M (2003) Inhibition of aquaporin-4 expression in astrocytes by RNAi determines alteration in cell morphology, growth, and water transport and induces changes in ischemia-related genes. FASEB J, 17, 1508-1510
207. Collins MA, Moon K-H, Tajuddin N, Neafsey EJ, & Kim H-Y (2013) Docosahexaenoic acid (DHA) prevents binge ethanol-dependent aquaporin-4 elevations while inhibiting neurodegeneration: Experiments in rat adult-Age entorhinohippocampal slice cultures. Neurotox Res, 23, 105-110
208. Suzuki Y, Nakamura Y, Yamada K, Huber VJ, Tsujita M, & Nakada T (2012) Aquaporin-4 positron emission tomography imaging of the human brain: First report. J Neuroimaging, 23, 219-223
209. Badaut J (2010) Aquaglyceroporin 9 in brain pathologies. Neuroscience, 168, 1047-1057
210. Papadopoulos MC, & Verkman AS (2013) Aquaporin water channels in the nervous system. Nat Rev Neurosci, 14, 265-277
211. Amiry-Moghaddam M, Lindland H, Zelenin S, Roberg BA, Gundersen BB, Petersen P, Rinvik E, Torgner IA,&Ottersen OP (2005) Brain mitochondria contain aquaporin water channels: Evidence for the expression of a short AQP9 isoform in the inner mitochondrial membrane. FASEB J, 19, 1459-1467
212. Liu H, Yang M, Qiu G, Zhuo F, Yu W, Sun S, & Xiu Y (2012) Aquaporin 9 in rat brain after severe traumatic brain injury. Arq Neuropsiquiatr, 70, 214-220
213. Jäger R, & Fearnhead HO (2012) "Dead Cells Talking": The silent form of cell death is not so quiet. Biochem Res Int, 2012, 453838
214. Mollereau B, Perez-Garijo A, Bergmann A, Miura M, Gerlitz O, Ryoo HD, Steller H, & Morata G (2013) Compensatory proliferation and apoptosis-induced proliferation: A need for clarification. Cell Death Differ, 20, 181
215. Ryoo HD, & Bergmann A (2012) The role of apoptosisinduced proliferation for regeneration and cancer. Cold Spring Harb Perspect Biol, 4, a008797
216. Yamada M, Kida K, Amutuhaire W, Ichinose F, & Kaneki M (2010) Gene disruption of caspase-3 prevents MPTPinduced Parkinson's disease in mice. Biochem Biophys Res Commun, 402, 312-318
217. Hartmann A, Hunot S, Michel PP, Muriel MP, Vyas S, Faucheux BA, Mouatt-Prigent A, Turmel H, Srinivasan A, Ruberg M, Evan GI, Agid Y, & Hirsch EC (2000) Caspase-3: A vulnerability factor and final effector in apoptotic death of dopaminergic neurons in Parkinson's disease. Proc Natl Acad Sci USA, 97, 2875-2880
218. Fortt R, Smith G, Awais RO, Luthra SK, & Aboagye EO (2012) Automated GMP synthesis of [(18)F]ICMT-11 for in vivo imaging of caspase-3 activity. Nucl Med Biol, 39, 1000-1005
219. Aboagye EO (2010) The future of imaging: Developing the tools for monitoring response to therapy in oncology: The 2009 Sir James MacKenzie Davidson Memorial lecture. Br J Radiol, 83, 814-822
220. Nguyen Q-D, Challapalli A, Smith G, Fortt R, & Aboagye EO (2012) Imaging apoptosis with positron emission tomography: "Bench to bedside" development of the caspase-3/7 specific radiotracer [(18)F]ICMT-11. Eur J Cancer, 48, 432-440
221. Tait JF (2008) Imaging of apoptosis. J Nucl Med, 49, 1573-1576
222. Cao W, Huang J, Wu J, Cao G, He Y, Hu D, Sun S, An R, & Zhang Y (2007) Study of 99mTc-Annexin V uptake in apoptotic cell models of Parkinson's disease. Nucl Med Commun, 28, 895-901
223. Reshef A, Shirvan A, Akselrod-Ballin A, Wall A, & Ziv I (2010) Small-molecule biomarkers for clinical PET imaging of apoptosis. J Nucl Med, 51, 837-840
224. Hu S, Kiesewetter DO, Zhu L, Guo N, Gao H, Liu G, Hida N, Lang L, Niu G,&Chen X (2012) Longitudinal PET imaging of doxorubicin-induced cell death with 18F-Annexin V. Mol Imaging Biol, 14, 762-770
225. DeWolde H, Pruim J, Mastik MF, Koudstaal J, &Molenaar WM (1997) Proliferative activity in human brain tumors: Comparison of histopathology and L-[1-(11)C]tyrosine PET J Nucl Med, 38, 1369-1374
226. Onda K, Davis RL, Wilson CB, & Hoshino T (1994) Regional differences in bromodeoxyuridine uptake, expression of Ki-67 protein, and nucleolar organizer region counts in glioblastoma multiforme. Acta Neuropathol, 87, 586-593
227. Plaat B, Kole A, Mastik M, Hoekstra H, Molenaar W, & Vaalburg W (1999) Protein synthesis rate measured with L-[1-11C]tyrosine positron emission tomography correlates with mitotic activity and MIB-1 antibody-detected proliferation in human soft tissue sarcomas. Eur J Nucl Med, 26, 328-332
228. Asari S, Fujimoto K, Miyauchi A, SatoT, Nakano I,&Muramatsu S (2011) Subregional 6-[18F]fluoro-L-m-Tyrosine uptake in the striatum in Parkinson's disease. BMC Neuro, 11, 35
229. Kong F-L, Ali MS, Rollo A, Smith DL, Zhang Y, Yu D-F, & Yang DJ (2012) Development of tyrosine-based radiotracer 99mTc-N4-Tyrosine for breast cancer imaging. J Biomed Biothecnol, 2012, 671708
230. Gallagher CL, Christian BT, Holden JE, Dejesus OT, Nickles RJ, Buyan-Dent L, Bendlin BB, Harding SJ, Stone CK, Mueller B, & Johnson SC (2011) A within-subject comparison of 6-[18F]fluoro-m-Tyrosine and 6-[18F]fluoro-L-dopa in Parkinson's disease. Mov Disord, 26, 2032-2038
231. Rahmim A,&Zaidi H (2008)PETversusSPECT: Strengths, limitations and challenges. Nucl MedCommun, 29, 193-207